Denali Therapeutics Inc. (DNLI)

NASDAQ: DNLI · IEX Real-Time Price · USD

15.43

+0.47 (3.14%)

At close: Apr 26, 2024, 4:00 PM

15.72

+0.29 (1.88%)

After-hours: Apr 26, 2024, 6:49 PM EDT

Denali Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	330.53	108.46	48.66	335.66	26.68	129.16	0	0	0
Revenue Growth (YoY)	204.74%	122.90%	-85.50%	1158.19%	-79.34%	-	-	-	-
Gross Profit	330.53	108.46	48.66	335.66	26.68	129.16	0	0	0
Selling, General & Admin	103.35	90.48	79.06	60.33	46.48	32.35	15.68	11.73	5.11
Research & Development	423.88	358.73	265.35	212.62	193.38	143.18	74.46	75.7	11.57
Operating Expenses	527.23	449.21	344.41	272.94	239.86	175.53	90.14	87.43	16.68
Operating Income	-196.7	-340.74	-295.75	62.72	-213.18	-46.37	-90.14	-87.43	-16.68
Interest Expense / Income	0	0	0	0	0	0	0	0	0.11
Other Expense / Income	-51.51	-14.77	-4.6	-9.24	-15.22	-10.13	-1.96	-0.78	-
Pretax Income	-145.19	-325.97	-291.16	71.96	-197.97	-36.24	-88.19	-86.65	-16.79
Income Tax	0.03	0.02	-0.58	0.82	-0.35	0	0	0	0
Net Income	-145.22	-325.99	-290.58	71.14	-197.61	-36.24	-88.19	-86.65	-16.79
Shares Outstanding (Basic)	137	126	122	120	96	93	15	6	3
Shares Outstanding (Diluted)	137	126	122	-	96	93	15	6	3
Shares Change	9.43%	3.30%	1.34%	25.43%	3.22%	518.96%	132.92%	113.70%	-
EPS (Basic)	-1.06	-2.60	-2.39	0.65	-2.07	-0.39	-5.89	-13.49	-5.58
EPS (Diluted)	-1.06	-2.60	-2.39	0.63	-2.07	-0.39	-5.89	-13.49	-5.58
Free Cash Flow	-370.93	-262.55	-219.89	413.06	-169.5	46.72	-79.51	-78.04	-18.11
Free Cash Flow Per Share	-2.70	-2.09	-1.81	3.44	-1.77	0.50	-5.31	-12.15	-6.03
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-	-	-
Operating Margin	-59.51%	-314.16%	-607.78%	18.69%	-799.10%	-35.90%	-	-	-
Profit Margin	-43.94%	-300.56%	-597.15%	21.19%	-740.74%	-28.06%	-	-	-
Free Cash Flow Margin	-112.22%	-242.06%	-451.88%	123.06%	-635.34%	36.17%	-	-	-
Effective Tax Rate	-	-	-	1.14%	-	-	-	-	-
EBITDA	-128.47	-315.59	-282.56	80.49	-189.97	-28.83	-85.1	-85.18	-16.56
EBITDA Margin	-38.87%	-290.96%	-580.68%	23.98%	-712.10%	-22.32%	-	-	-
Depreciation & Amortization	16.73	10.38	8.59	8.53	7.99	7.42	3.08	1.47	0.12
EBIT	-145.19	-325.97	-291.16	71.96	-197.97	-36.24	-88.19	-86.65	-16.68
EBIT Margin	-43.93%	-300.54%	-598.34%	21.44%	-742.05%	-28.06%	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).